CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA regarding their cancer immunotherapy. 9 Out of the Last 10 Summers this ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the pricing of a best-efforts offering of ...
CEL-SCI Corporation (NYSE:CVM) saw its stock drop 31% following the announcement of a $10 million public offering priced well below its prior closing value. The clinical-stage cancer immunotherapy ...
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts ...
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its offering of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results